Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as IGF-IR
BMS-754807 · 4 trials · 6 indications
| Arm | Type | Description |
|---|---|---|
| BMS-754807 | EXPERIMENTAL | - |
| A | EXPERIMENTAL | Combination |
| Sequential allocation of patients in two dosing schedules | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-754807 | DRUG | Tablets, Oral, 20 mg, 30 mg, 50 mg, 70 mg, 100 mg, 130 mg, 160 mg, 200 mg once daily, 3-5 months, depending on response |
| trastuzumab (Herceptin®) | DRUG | IV solution, IV, 4mg/kg Day 1 loading dose, 2mg/kg once weekly, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop |
| Paclitaxel | DRUG | Vials, IV, 200 mg/m2, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request |
| Carboplatin | DRUG | Vials, IV, 6 mg/mL.min, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request |
Inclusion Criteria: * Advanced or metastatic solid tumors for whom the standard of care is ineffective or inappropriate * Life expectancy of at least 3 months * Eastern Cooperative Oncology Group performance 0-1 Exclusion Criteria: * Any disorder with dysregulation of glucose homeostasis * Dumpin...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BMS-754807 is an investigational small molecule being studied in oncology for the treatment of advanced or metastatic solid tumors, neoplasms, and HER2-positive breast cancer. It has been evaluated in Phase 1 clinical trials, both as a single agent and in combination with other therapies such as paclitaxel, carboplatin, and Herceptin.
BMS-754807 targets insulin receptor (INSR) and insulin-like growth factor 1 receptor (IGF1R). It is classified as an inhibitor of these targets. By inhibiting INSR and IGF1R, BMS-754807 interferes with signaling pathways that can promote tumor cell growth and survival.
BMS-754807 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. Bristol-Myers Squibb is the sponsor of the clinical trials evaluating this agent.
BMS-754807 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA for any indication. All completed trials were Phase 1 studies designed to assess safety, tolerability, and dosing in patients with solid tumors or breast cancer.
BMS-754807 has been evaluated in completed Phase 1 trials including NCT00898716 in Japanese patients with solid tumors, NCT00793897 in combination with paclitaxel and carboplatin, NCT00788333 with Herceptin in HER2-positive breast cancer, and NCT00569036 in advanced or metastatic solid tumors. All trials are completed.